First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles
The FDA approved Provention Bio Inc’s (NASDAQ:PRVB) Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in…
FDA Grants Approval Of Tzield To Provention Bio
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes
Oramed Announces Additional Safety, Efficacy Data From Phase 2 Clinical Trial Of ORMD-0801 For NASH; Achieved Primary Endpoint
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,
Incannex Initiates BA/BE Clinical Trial Evaluating IHL-42X In Obstructive Sleep Apnoea
Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023.
Takeda Announces Phase 3 Trial Of ICLUSIG Met Primary Endpoint In Newly-Diagnosed Ph+ ALL, A Setting With No Targeted Treatments Approved In The US
- The PhALLCON Study Is the First Global, Phase 3, Registrational, and Only Head-To-Head Clinical Trial Comparing Two TKIs in Frontline Ph+ ALL
- Primary Endpoint Result Shows Superiority Compared to Imatinib as
atai Life Sciences And Massachusetts General Hospital Announce Initiation Of Clinical Study Investigating Neuroplasticity Biomarkers In Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study
Evaxion Announces Results From Phase 1/2A Clinical Trial Of Personalized DNA Cancer Immunotherapy EVX-02
Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical
Immunic Reports New Data From Phase 2 EMPhASIS Trial Of Vidofludimus Calcium In Relapsing-Remitting Multiple Sclerosis Supporting The Drug’s Neuroprotective Potential
– Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening –
– Virtual Multiple Sclerosis R&D Day to be Held Today, November 17,